Avanzanite Bioscience

Greetings from Barcelona 🇪🇸 where Avanzanite team attends 2024 The European Society of Cataract and Refractive Surgeons (ESCRS) European Society of Cataract and Refractive Surgeons (ESCRS) congress. We look forward to conversations with #ophtalmologists how to set new standards in the treatment of #acanthamoebakeratitis given recent breakthroughs. Avanzanite team on-site: Friso W. M. Langen Sotiris Botozis Andrzej Cebula Agata Wiktorowicz - Paluch Adam Andrzej Plich

Wow! Our second #orphan medicine now approved by the European Commission. We are grateful to: - our R&D partners at SIFI under Fabrizio Chines leadership - the healthcare professionals, in particular professor John Dart of Moorfields Eye Hospital, London and UCL, a principal investigator of the pivotal phase III trial, - patients and their families who participated in the trials for more than 16 years of dedication and hard work that made this day possible We are committed as an organisation to collaborating with local health authorities to ensure sustainable access agreements across 26 European countries - so we can save the #eyes of as many eligible patients as possible. #acanthamoebakeratitis, #ophtalmology, #eye, #orphan, #raredisease, #akwarriors, #innovation, #research https://lnkd.in/eXXPEesX

Nobody should be left behind when facing #acanthamoebakeratitis, a #rare #eye infection that ofren leads to #blindness and eye removal. At Avanzanite Bioscience, we are proud to partner with SIFI so that people in 26 European countries, like Alice Sotero, get immediate support to take them out of darkness, excruciating pain and get back their vision. SIFI, under the leadership of Fabrizio Chines, and supported by Alessandro Benetton, has dedicated more than 16 years of #research and #development into this area. No one else dared to do that. And now this R&D is powering up Olympic atheltes 🏆 . https://lnkd.in/eDE7SsjY

Nobody fighting such a devastating disease should be left behind.

4 JUNE, SAN DIEGO 🇺🇸. Thanks to the full Theater of 50 partners and investors that attended Avanzanite Bioscience first ever BIO International Convention podium presenration by Eva Cruz de Castro, Chief Alliance Officer. This marks the new era for Avanzanite Bioscience. To accelerate growth, build new alliances, expand portfolio, and broaden territories. All in line with our vision of 30 medicines by 2032 to ensure NO ONE is LEFT BEHIND when dacing monstrous #rarediseases. Contact Eva Cruz de Castro if you want to join us in this mission.

Find more info about the presentation today at the official website here: https://lnkd.in/eCuAHvyB See you later today in San Diego!

BREAKTHROUGH: expanding footprint to 26 European countries with second #orphan drug. This CHMP opinion is a massive step forward for Avanzanite Bioscience in building strong specialty pharmaceutical company – to eventually achieve our vision that NO ONE IS LEFT BEHIND when facing monstrous rare diseases, such such as #acanthamoebakeratitis. People should have access to this first licensed drug regardless of where in Europe they live. At Avanzanite Bioscience, we are committed to make it happen across 26 countries. Congratulations to SIFI leaders and their R&D team, their investors 21 Invest, principal investigator John Dart from Moorfields Eye Hospital, London and many more involved for such an epic success after more than 15-year journey! It is a gargantuan effort to develop novel #orphan medicine in the areas of huge unmet need. Everyone involved is a hero that we highly respect. https://lnkd.in/ea5Duvb6

PARIS 🇫🇷. 24–26 MAY. Latest #acanthamoebakeratitis research presented at the European Society of Cornea & Ocular Surface Disease Specialists (EuCornea) Congress! Congratulations to the organisers and for the host prof. Béatrice COCHENER-LAMARD for a very successful 2024 congress. Year after year, the overall attendance is increasing. And broader range of countries are are represented notably with numerous delegates from the US 🇺🇸. This year the conference took place in magnificent Campus Pierre & Marie Curie Centre at the Sorbonne University. We were impressed by the growing amount of research into #acanthamoebakeratitis presented at the congress with impressive attendance despite beatiful sunny 🌞 weather in Paris: ➡ First, congratulations to Dr Katie Curro, from The Netherlands 🇳🇱 , for the Best Paper Reward “Diagnosing and monitoring the characteristics of Acanthamoeba keratitis using slit scanning and laser scanning in vivo confocal microscopy.  ➡ Prof. Paolo Rama from Italy 🇮🇹 , a phase III ODAK trial investigator, gave a great talk about “New Medical treatment for #acanthamoeba and #fungalkeratitis” at the "What’s New in Corneal Infection" symposium moderated by prof. Jesper Hjortdal, Aarhus Universitetshospital in Denmark🇩🇰 and Bruce Allan from the UK 🇬🇧 . ➡ Dr Lida Lalou, from the University General Hospital of Athens 🇬🇷, presented a case report titled "A novel approach to #acanthamoebakeratitis treatment". Avanzanite Bioscience was represented by Cecilia Bröms-Thell, General Manager Nordic Countries, and Adam Andrzej Plich, Founder & CEO. We shared a booth with our partner SIFI – Johan Druelle and Jelle Kleijn, a leading Italian ophthalmic healthcare company, raising awareness about the impact of #acanthamoebakeratitis well beyond the initial acute treatment phase, leaving patients with trauma for life. NO ONE FACING SUCH A MONSTROUS DISEASE SHOULD BE LEFT BEHIND.

What an inspiring & joyful evening it was! An event like that is a reminder for our team at Avanzanite Bioscience of who we are and what are standing for. We are #grateful to all people that have made this event such a success! We were honoured by: ➡ Prof. Lutz Weber, Head of Paediatric Nephrology Clinic at the University Hospital in #Cologne ➡ Prof. Lars Pape, Head of Paediatric Nephrology Clinic and Transplants at the University Hospital in #Essen, welcoming all the guest and recognising profoundly the work Nephrokids are doing. We are particularly grateful to all of those that have given their items for #auction for free, some of which very very unique (and with high monetary value, priceless in some cases). And for courage to tell amazing story of the items in front of the audience. The auction itself raised more than 5000 EUR! Thanks to all the generous bidders! Finally, thanks for more than 60 hashtag #biotech executives, #investors, #rare disease advocates that came from – extraordinary 18 countries in Europe! – to be part of the event and recognise the work of Nephrokids (led by Michaela and Oliver Peer). You've made the atmosphere joyful and you were fiercely auctioneering. Each one of you had to pay to attend (as that wast the rule for all!) and directly helped raised the funds for nephrokids. And some of you have made generous private discreet donations, too.

Exploring strategic options for Europe 🇪🇺 with your hashtag #orphandrug? Reach out to Eva Cruz de Castro to meet in the sunny #SanDiego 🇺🇸 at the upcoming Biotechnology Innovation Organization International Convention to explore a partnership with Avanzanite Bioscience. Avanzanite acquires, licenses or distributes market-ready medicines for #rarediseases and commercialises them everywhere in Europe, even where nobody else will – so that NO ONE'S LEFT BEHIND. If that resonates, email: [email protected]. You should particularly meet Eva Cruz de Castro if you face challenges in Europe 🇪🇺. Perhaps, there are very few patients that could use your medicine. Or the market access issues are overwhelming. Or simply, you only have a bandwith to go to to 2–3 countries at launch. Whatever is the trouble, we love challenges. Our confidence is not superficial. We have an unrivalled track record in market access and market development. And we will make sure that all back-end operations are running smoothly - distribution, pharmacovigilance, medical information, quality, compliance etc. And when needed, we will step in a bit earlier to tie things up together - with regulatory submission, some outstanding CMC work, patent prosecution etc.